Press Releases

Therapeutic Solutions International Announces Exclusive Patent License Agreement with Subsidiary Emvolio, Inc.

Therapeutic Solutions files Patent on Methods of Re-Activating Dormant Memory Cells with Anticancer Activity

Therapeutic Solutions International Announces Exclusive Patent License Agreement with Subsidiary Emvolio, Inc.

Therapeutic Solutions files new Patent on Augmentation of Anti-Tumor Immunity by Mifepristone and Analogues Thereof

Therapeutic Solutions International Announces Exclusive Patent License Agreement to innaMune with its Subsidiary Emvolio, Inc.

Therapeutic Solutions files Patent on Blood Derived Innate Immune System Stimulator

Therapeutic Solutions International Announces Exclusive Patent License Agreement with its Subsidiary Emvolio, Inc.

Therapeutic Solutions files new Patent on Targeting the Tumor Microenvironment through Nutraceutical Based Immunoadjuvants

Therapeutic Solutions International Announces Appointment of Dr. Thomas E. Ichim to its Subsidiary Emvolio, Inc.

Therapeutic Solutions International’s Subsidiary OmniBiome, Inc. Announces First Oral Microbiome Therapy for Periodontal Disease

Therapeutic Solutions International’s Subsidiary, Emvolio, Inc., Files Investigational New Drug Application for StemVacs Cancer Immunotherapy

Therapeutic Solutions International Announces Filing of new Immunotherapy Patent and Exclusive Patent License Agreement with Subsidiary Emvolio, Inc.

Therapeutic Solutions Receives Allowance on Patent Claim from the US Patent Office Covering ProJuvenol® Active Ingredient Pterostilbene in Cancer Immunotherapies

Therapeutic Solutions International Reports Augmentation of Cancer Immunotherapy Using Pterostilbene

Therapeutic Solutions International Announces New Liposomal Products

Therapeutic Solutions International’s Subsidiary MolecuVax, Inc. Announces Licensing of “Universal Cancer Vaccine” With Demonstrated Efficacy in Breast Cancer

Therapeutic Solutions International Files Patent Covering ProJuvenol© and Its Active Ingredient Pterostilbene

Therapeutic Solutions International’s Subsidiary MolecuVax, Inc. to Initiate Cancer Immunotherapy Clinical Trial Aimed at Eradicating Cancer Stem Cells Using MVAX-001

Therapeutic Solutions International Announces the Appointment of Dr. Hong Ma as Chief Scientific Officer

Therapeutic Solutions International Announces the Licensing of Exosome Technology to MolecuVax, Inc.

Therapeutic Solutions International Licenses Dexosome Clinical Stage Cancer Immunotherapy Product From Gustave Roussy European Cancer Centre

Therapeutic Solutions International Announces the Appointment of BioPharmaceutical Pioneer Thomas E. Ichim, Ph.D to Board of Directors

Therapeutic Solutions International Announces the Appointment of Dr. Barry Glassman to the TSI Scientific Advisory Board

Therapeutic Solutions International Announces the Licensing of Probiotic Technology to OmniBiome, Inc.

Therapeutic Solutions International Files Patent on Anticancer Nanotechnology Based Immunotherapy

Therapeutic Solutions International Announces the Licensing of Patents to OmniBiome and the Appointment of Iryna Dzieciuch, M.S. as Chief Executive Officer of OmniBiome

Therapeutic Solutions International, Inc. Announces the Appointment of Professor David P. Hajjar, Ph.D. to the TSI Scientific Advisory Board

Therapeutic Solutions International, Inc. Announces the Appointment of Vijay Mahant, Ph.D., M.S. to the TSI Scientific Advisory Board

Therapeutic Solutions International, Inc. Announces the Appointment of Francesco M Marincola, MD, FACS, to the TSI Scientific Advisory Board

Therapeutic Solutions International Announces the Appointment of Michael G. Agadjanyan, Ph.D. to Company Scientific Advisory Board

Therapeutic Solutions International Announces the Appointment of Harry M. Lander, Ph.D. to the TSI Scientific Advisory Board

Therapeutic Solutions International, Inc. Announces the Appointment of Santosh Kesari, M.D., Ph.D. to Company Scientific Advisory Board

Therapeutic Solutions International Files Patent on Immune Therapy Medical Device to Prevent Preterm Labor

Therapeutic Solutions International Develops Cytokine Based Diagnostic Test for Preterm Labor and Complications of Pregnancy

Therapeutic Solutions International Announces Engagement With PLS CPA’s

Therapeutic Solutions International Files Patent on Cytokine Modulation to Prevent Pregnancy Loss and Pre-Term Labor

Therapeutic Solutions International Acquires Preterm Labor and Miscarriage Intellectual Property From OmniBiome

Therapeutics Inc. Company Expands Immunotherapy Based Product Pipeline by Filing New Patent Application

Therapeutic Solutions International Files Patent on Cancer Immune Modulation Using Its ProJuvenol™ Product

Therapeutic Solutions Announces Shipping of ProJuvenol™ and T-Rx™

Therapeutic Solutions Announces New Product Line and Launch of E-Commerce Platform

Therapeutic Solutions International Updates Shareholders 2-03-2015

Therapeutic Solutions International, Inc. Announces New Division 3-26-2014

© 2016: Therapeutic Solutions International, Inc., All Rights Reserved | Awesome Theme by: D5 Creation | Powered by: WordPress